Clinical standards for the management of adverse effects during treatment for TB

Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE. 65/81 invited experts participated in a Delphi process using a 5-point Likert scale to score draft sta...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The international journal of tuberculosis and lung disease Ročník 27; číslo 7; s. 506
Hlavní autoři: Singh, K P, Carvalho, A C C, Centis, R, D Ambrosio, L, Migliori, G B, Mpagama, S G, Nguyen, B C, Aarnoutse, R E, Aleksa, A, van Altena, R, Bhavani, P K, Bolhuis, M S, Borisov, S, van T Boveneind-Vrubleuskaya, N, Bruchfeld, J, Caminero, J A, Carvalho, I, Cho, J G, Davies Forsman, L, Dedicoat, M, Dheda, K, Dooley, K, Furin, J, García-García, J M, Garcia-Prats, A, Hesseling, A C, Heysell, S K, Hu, Y, Kim, H Y, Manga, S, Marais, B J, Margineanu, I, Märtson, A-G, Munoz Torrico, M, Nataprawira, H M, Nunes, E, Ong, C W M, Otto-Knapp, R, Palmero, D J, Peloquin, C A, Rendon, A, Rossato Silva, D, Ruslami, R, Saktiawati, A M I, Santoso, P, Schaaf, H S, Seaworth, B, Simonsson, U S H, Singla, R, Skrahina, A, Solovic, I, Srivastava, S, Stocker, S L, Sturkenboom, M G G, Svensson, E M, Tadolini, M, Thomas, T A, Tiberi, S, Trubiano, J, Udwadia, Z F, Verhage, A R, Vu, D H, Akkerman, O W, Alffenaar, J W C, Denholm, J T
Médium: Journal Article
Jazyk:angličtina
Vydáno: France 01.07.2023
Témata:
Drug-Related Side Effects and Adverse Reactions - etiology
Health Personnel
Humans
Hypersensitivity
Tuberculosis - diagnosis
Tuberculosis - drug therapy
ISSN:1815-7920, 1815-7920
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE. 65/81 invited experts participated in a Delphi process using a 5-point Likert scale to score draft standards. We identified eight clinical standards. Each person commencing treatment for TB should: Standard 1, be counselled regarding AE before and during treatment; Standard 2, be evaluated for factors that might increase AE risk with regular review to actively identify and manage these; Standard 3, when AE occur, carefully assessed and possible allergic or hypersensitivity reactions considered; Standard 4, receive appropriate care to minimise morbidity and mortality associated with AE; Standard 5, be restarted on TB drugs after a serious AE according to a standardised protocol that includes active drug safety monitoring. In addition: Standard 6, healthcare workers should be trained on AE including how to counsel people undertaking TB treatment, as well as active AE monitoring and management; Standard 7, there should be active AE monitoring and reporting for all new TB drugs and regimens; and Standard 8, knowledge gaps identified from active AE monitoring should be systematically addressed through clinical research. These standards provide a person-centred, consensus-based approach to minimise the impact of AE during TB treatment.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1815-7920
1815-7920
DOI:10.5588/ijtld.23.0078